Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 4, 2007, Pages 804-811

  Zhang, Guo Xing ^a   Ohmori, Koji ^a   Nagai, Yukiko ^a   Fujisawa, Yoshihide ^a   Nishiyama, Akira ^a   Abe, Youichi ^a   Kimura, Shoji ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Adrenergic receptor agonist; Angiotensin antagonist; Cardiac hypertrophy; Oxidative stress

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR; COLLAGEN; ISOPRENALINE; OLMESARTAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HEART RATE; HEART STIMULATION; HEART VENTRICLE HYPERTROPHY; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ANGIOTENSINS; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CARDIOMEGALY; COLLAGEN TYPE I; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FIBROSIS; ISOPROTERENOL; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NADPH OXIDASE; OXIDATIVE STRESS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ADRENERGIC, BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPEROXIDES;

MUS;

EID: 34047161460     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.01.012     Document Type: Article

References (38)

1. McMurray J.J.V., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
2. SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325 (1991) 293-302
3. Bristow M.R. Mechanism of action of β-blocking agents in heart failure. Am. J. Cardiol. 80 (1997) 26L-40L
4. Sekiguchi K., Li X., Coker M., Flesch M., Barger P., Sivasubramanian N., et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc. Res. 63 (2004) 433-442
5. Scheuer J. Catecholamines in cardiac hypertrophy. Am. J. Cardiol. 83 (1999) 70H-74H
6. Rockman H.A., Koch W.J., and Lefkowitz R.J. Seven-transmembrane-spanning receptors and heart function. Nature 415 (2002) 206-212
7. Makino T., Hattori Y., Mastuda N., Onozuka H., Sakuma I., and Kitabatake A. Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on signaling in heart failure produced by myocardial infarction in rabbits: reversal of altered expression of β-adrenoceptor kinase and Giα. J. Pharmacol. Exp. Ther. 304 (2003) 370-379
8. Takahashi T., Anzai T., Yoshikawa T., Maekawa Y., Mahara K., Iwata M., et al. Angiotensin receptor blockade improves myocardial beta-adrenergic receptor signaling in postinfarction left ventricular remodeling: a possible link between beta-adrenergic receptor kinase-1 and protein kinase C epsilon isoform. J. Am. Coll. Cardiol. 43 (2004) 125-132
9. Barki-Harrington L., Luttrell L.M., and Rockman H.A. Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108 (2003) 1611-1618
10. Keith M., Geranmayegan A., Sole M.J., Kurian R., Robinson A., Omran A.S., et al. Increased oxidative stress in patients with congestive heart failure. J. Am. Coll. Cardiol. 31 (1998) 1352-1356
11. Zhang G.-X., Kimura S., Nishiyama A., Shokoji T., Rahman M., and Abe Y. ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension 43 (2004) 117-124
12. Kimura S., Zhang G.-X., Nagai Y., Miyata K., Nishiyama A., Shokoji T., et al. Time-dependent transition of tempol-sensitive reduction of blood pressure in angiotensin II-induced hypertension. J. Hypertens 22 (2004) 2161-2168
13. Kimura S., Zhang G.-X., Nishiyama A., Shokoji T., Yao L., Fan Y.Y., et al. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 45 (2005) 438-444
14. Zhang G.-X., Kimura S., Nishiyama A., Shokoji T., Rahman M., Yao L., et al. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc. Res. 65 (2005) 230-238
15. Oliveira E.M., and Krieger J.E. Chronic b-adrenoceptor stimulation and cardiac hypertrophy with no induction of circulating rennin. Eur. J. Pharmacol. 520 (2005) 135-141
16. Leenen F.H., White R., and Yuan B. Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H2410-H2416
17. Yu Y., Ohmori K., Chen Y., Sato C., Kiyomoto H., Shinomiya K., et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J. Am. Coll. Cardiol. 44 (2004) 904-913
18. Sugaya T., Nishimatsu S., Tanimoto K., Takimoto E., Yamagishi T., Imamura K., et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 270 (1995) 18719-18722
19. Junqueira L.C., Bignolas G., and Brentani R.R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 11 (1979) 447-455
20. Kimura S., Zhang G.-X., Nishiyama A., Shokoji T., Yao L., et al. Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 45 (2005) 860-866
21. Mohazzab K.M., and Wolin M.S. Sites of superoxide anion production detected bylucigenin in calf pulmonary artery smooth muscle. Am. J. Physiol. 267 (1994) L815-L822
22. Heymes C., Bendall J.K., Ratajczak P., Cave A.C., Samuel J.L., Hasenfuss G., et al. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll. Cardiol. 41 (2003) 2164-2171
23. Brown R.D., Ambler S.K., Mitchell M.D., and Long C.S. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 657-687
24. Kass D.A., Bronzwaer J.G., and Paulus W.J. What mechanisms underlie diastolic dysfunction in heart failure?. Circ. Res. 94 (2004) 1533-1542
25. Shite J., Qin F., Mao W., Kawai H., Stevens S.Y., and Liang C. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J. Am. Coll. Cardiol. 38 (2001) 1734-1740
26. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., and Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J. Mol. Cell Cardiol. 34 (2002) 379-388
27. Tsujimoto I., Hikoso S., Yamaguchi O., Kashiwase K., Nakai A., Takeda T., et al. The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy. Hypertension 45 (2005) 921-926
28. Wassmann S., Czech T., Van Eickels M., Fleming I., Bohm M., and Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110 (2004) 3062-3067
29. Li X., Rayford H., and Uhal B.D. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am. J. Pathol. 163 (2003) 2523-2530
30. Sasaki K., Murohara T., Ikeda H., Sugaya T., Shimada T., Shintani S., et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J. Clin. Invest. 109 (2002) 603-611
31. Cervenka L., Mitchell K.D., Oliverio M.I., Coffman T.M., and Navar L.G. Renal function in the AT1A receptor knockout mouse during normal and volume-expanded conditions. Kidney Int. 56 (1999) 1855-1862
32. Harada K., Komuro I., Shiojima I., Hayashi D., Kudoh S., Mizuno T., et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 97 (1998) 1890-1892
33. 1B receptors in mouse aorta and heart. Eur. J. Pharmacol. 485 (2004) 243-249
34. Autelitano D.J., Ridings R., Pipolo L., and Thomas W.G. Adrenomedullin inhibits angiotensin AT1A receptor expression and function in cardiac fibroblasts. Regul. Pept. 112 (2003) 131-137
35. Wang X., Nickenig G., and Murphy T.J. The vascular smooth muscle type I angiotensin II receptor mRNA is destabilized by cyclic AMP-elevating agents. Mol. Pharmacol. 52 (1997) 781-787
36. Makita N., Iwai N., Inagami T., and Badr K.F. Two distinct pathways in the down-regulation of type-1 angiotension II receptor gene in rat glomerular mesangial cells. Biochem. Biophys. Res. Commun. 185 (1992) 142-146
37. Jones E.S., Black M.J., and Widdop R.E. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J. Mol. Cell Cardiol. 37 (2004) 1023-1030
38. Golomb E., Abassi Z.A., Cuda G., Stylianou M., Panchal V.R., Trachewsky D., et al. Angiotensin II maintains, but dose not mediate, isoproterenol-induced cardiac hypertrophy in rats. Am. J. Physiol. Heart Circ. Physiol. 67 (1994) H1496-H1506